Article

Trametinib in the treatment of advanced lung adenocarcinoma with KRAS G12D mutation: a case report and literature review

2024-02-06

Abstract excerpt

The lung cancer poses a great threat to the patients’ health and social activities. Luckily, epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have greatly improved the response of patients getting EGFR-mutated non-small cell lung cancer (NSCLC), but the targeted therapy of KRAS mutations in lung cancer is still being explored; Currently, the effectiveness of drugs for KRAS mutations NSCLC i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5ab35393-989b-53c2-be4e-994e766e9bd6
DOI: 10.21203/rs.3.rs-3787479/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Trametinib in the treatment of advanced lung adenocarcinoma with KRAS G12D mutation: a case report and literature reviewDOI 10.21203/rs.3.rs-3787479/v1Read

[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].Semantic proximity Read

[A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation Treated with Anlotinib].Semantic proximity Read

Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential.Semantic proximity Read

[Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].Semantic proximity Read

Current perspectives of KRAS in non-small cell lung cancer.Semantic proximity Read

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung CancerSemantic proximity Read

KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.Semantic proximity Read

KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.Semantic proximity Read

Limited role of KRAS mutation in guiding immunotherapy in advanced non-small-cell lung cancer.Semantic proximity Read

KRAS mutated Non-Small Lung Carcinoma: A Real World Context from the Indian subcontinent.Semantic proximity Read

Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancerSemantic proximity Read

KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies.Semantic proximity Read